First Hawaiian Bank acquired a new stake in shares of Baxter International Inc (NYSE:BAX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 21,256 shares of the medical instruments supplier’s stock, valued at approximately $1,639,000.
A number of other hedge funds have also modified their holdings of BAX. Bridgeworth LLC purchased a new position in Baxter International during the second quarter valued at approximately $102,000. Migdal Insurance & Financial Holdings Ltd. increased its holdings in Baxter International by 3,088.9% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,435 shares of the medical instruments supplier’s stock valued at $106,000 after buying an additional 1,390 shares during the period. Baker Ellis Asset Management LLC purchased a new position in Baxter International during the second quarter valued at approximately $111,000. Centaurus Financial Inc. purchased a new position in Baxter International during the second quarter valued at approximately $117,000. Finally, Whittier Trust Co. of Nevada Inc. increased its holdings in Baxter International by 84.4% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 1,748 shares of the medical instruments supplier’s stock valued at $126,000 after buying an additional 800 shares during the period. 83.10% of the stock is currently owned by institutional investors.
Several equities analysts recently issued reports on BAX shares. Zacks Investment Research raised shares of Baxter International from a “hold” rating to a “buy” rating and set a $87.00 price objective on the stock in a report on Tuesday, September 25th. Argus reaffirmed a “hold” rating on shares of Baxter International in a report on Tuesday, September 4th. JPMorgan Chase & Co. lifted their price target on shares of Baxter International from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Friday, July 27th. Piper Jaffray Companies lifted their price target on shares of Baxter International from $77.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, July 27th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and issued a $76.00 price target on shares of Baxter International in a report on Friday, July 27th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $77.77.
NYSE BAX opened at $70.47 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.00 and a current ratio of 2.62. Baxter International Inc has a 12-month low of $62.52 and a 12-month high of $78.38. The firm has a market capitalization of $38.70 billion, a price-to-earnings ratio of 26.34, a PEG ratio of 1.96 and a beta of 0.77.
Baxter International (NYSE:BAX) last released its quarterly earnings results on Thursday, July 26th. The medical instruments supplier reported $0.77 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.06. Baxter International had a net margin of 8.29% and a return on equity of 16.63%. The business had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.83 billion. During the same period in the previous year, the company earned $0.63 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. Sell-side analysts anticipate that Baxter International Inc will post 2.98 EPS for the current year.
In other news, SVP Giuseppe Accogli sold 17,647 shares of the business’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $77.27, for a total transaction of $1,363,583.69. Following the sale, the senior vice president now directly owns 59,452 shares of the company’s stock, valued at $4,593,856.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Carole J. Shapazian sold 5,400 shares of the business’s stock in a transaction on Wednesday, August 8th. The shares were sold at an average price of $72.97, for a total transaction of $394,038.00. Following the sale, the director now directly owns 15,248 shares in the company, valued at $1,112,646.56. The disclosure for this sale can be found here. 0.05% of the stock is owned by insiders.
Baxter International Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Featured Story: Cash Flow Analysis in Stock Selection
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.